A new 4-gene-based prognostic model accurately predicts breast cancer prognosis and immunotherapy response by integrating WGCNA and bioinformatics analysis DOI Creative Commons
Wenlong Chen,

Yakun Kang,

Wenyi Sheng

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 2, 2024

Background Breast cancer (BRCA) is a common malignancy in women, and its resistance to immunotherapy major challenge. Abnormal expression of genes important the occurrence development BRCA may also affect prognosis patients. Although many model scores have been developed, they are only applicable limited number disease subtypes. Our goal develop new prognostic score that more accurate wider range Methods patient data from The Cancer Genome Atlas database was used identify breast cancer-related (BRGs). Differential analysis BRGs performed using ‘limma’ package R. Prognostic were identified co-expression univariate Cox analysis. A predictive four established regression LASSO algorithm. Model performance evaluated K-M survival receiver operating characteristic curve ability signature immune microenvironment investigated. In vitro experiments validated POLQ function. Results study four-BRG outperformed conventional clinicopathological characteristics predicting outcomes effectively stratified patients into high- low-risk groups showed potential response immunotherapy. Notably, significant differences observed cell abundance between two groups. demonstrated knockdown significantly reduced viability, proliferation, invasion capacity MDA-MB-231 or HCC1806 cells. Conclusion 4-BRG has as an independent biomarker for treatment patients, complementing existing characteristics.

Language: Английский

HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker DOI Creative Commons
Karim Amrane,

Coline Le Meur,

Benjamin Besse

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 17, 2024

Since the advent of anti-PD1 immune checkpoint inhibitor (ICI) immunotherapy, cutaneous melanoma has undergone a true revolution with prolonged survival, as available 5-year updates for progression-free survival and overall demonstrate durable clinical benefit patients receiving ICI. However, almost half fail to respond treatment, or relapse sooner later after initial response therapy. Little is known about reasons these failures. The identification biomarkers seems necessary better understand this resistance. Among biomarkers, HLA-DR, component MHC II abnormally expressed in certain tumor types including unknown reasons, be an interesting marker. aim review, prepared by interdisciplinary group experts, take stock current literature on potential interest HLA-DR expression predictive biomarker ICI outcome.

Language: Английский

Citations

14
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement DOI Creative Commons
O. Vermeulen, Elisabeth Brouwer, Riemer H. J. A. Slart

et al.

Lara D. Veeken, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 9, 2024

Abstract Objectives To compare clinical characteristics, imaging findings and treatment requirements of patients with immune checkpoint inhibitor-mediated polymyalgia rheumatica (ICI-PMR) primary PMR. Methods This single centre, retrospective cohort study compared ICI-PMR in cancer (n = 15) to PMR 37). A comparison was made between symptoms, laboratory markers, ultrasonography, 18F-FDG-PET/CT related Results Patients less frequently fulfilled the EULAR/ACR classification criteria for (66.7%) than (97.3%). Morning stiffness, weight loss elevation ESR were seen ICI-PMR. No differences observed regarding presence inflammatory lesions on ultrasound shoulders hips two groups. The Leuven Leuven/Groningen scores significantly lower group. Finally, group could be managed glucocorticoid doses group, while this discontinued more quickly. Conclusion Our indicate that may have a milder course intense inflammation can relatively low dose. underscores should regarded as PMR-like syndrome.

Language: Английский

Citations

13
Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to Immunotherapy DOI Creative Commons
He Jiang, You Zhou, Lun‐Quan Sun

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Jan. 31, 2024

The accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER) causes ER stress and activates protein response (UPR). As an adaptive cellular to hostile microenvironments, such as hypoxia, nutrient deprivation, oxidative stress, chemotherapeutic drugs, UPR is activated diverse cancer types functions a dynamic tumour promoter development; this role indicates that regulation can be utilized target for treatment. T-cell exhaustion mainly refers effector T cells losing their expressing inhibitory receptors, leading immune evasion loss control. Emerging evidence suggests plays crucial exhaustion, evasion, resistance immunotherapy. In review, we summarize molecular basis activation, effect on emerging mechanisms chemotherapy immunotherapy resistance, agents therapeutics. An understanding therapeutic will helpful identify new modalities Video Abstract.

Language: Английский

Citations

12
Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better DOI Creative Commons

Jayalakshmi Thiruppathi,

Veena Vijayan, In‐Kyu Park

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 5, 2024

Cancer immunotherapy has made tremendous advancements in treating various malignancies. The biggest hurdle to successful would be the immunosuppressive tumor microenvironment (TME) and low immunogenicity of cancer cells. To make successful, ‘cold’ TME must converted ‘hot’ immunostimulatory status activate residual host immune responses. this end, equilibrium should broken, immunogenic cell death ought induced stimulate tumor-killing cells appropriately. Photodynamic therapy (PDT) is an efficient way inducing (ICD) disrupting immune-restrictive tissues. PDT trigger a chain reaction that have ICD-induced antigens presented In principle, strategic combination synergize enhance therapeutic outcomes many intractable tumors. Novel technologies employing nanocarriers were developed deliver photosensitizers immunotherapeutic efficiently. New-generation nanomedicines been for recent years, which will accelerate clinical applications.

Language: Английский

Citations

12
A new 4-gene-based prognostic model accurately predicts breast cancer prognosis and immunotherapy response by integrating WGCNA and bioinformatics analysis DOI Creative Commons
Wenlong Chen,

Yakun Kang,

Wenyi Sheng

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 2, 2024

Background Breast cancer (BRCA) is a common malignancy in women, and its resistance to immunotherapy major challenge. Abnormal expression of genes important the occurrence development BRCA may also affect prognosis patients. Although many model scores have been developed, they are only applicable limited number disease subtypes. Our goal develop new prognostic score that more accurate wider range Methods patient data from The Cancer Genome Atlas database was used identify breast cancer-related (BRGs). Differential analysis BRGs performed using ‘limma’ package R. Prognostic were identified co-expression univariate Cox analysis. A predictive four established regression LASSO algorithm. Model performance evaluated K-M survival receiver operating characteristic curve ability signature immune microenvironment investigated. In vitro experiments validated POLQ function. Results study four-BRG outperformed conventional clinicopathological characteristics predicting outcomes effectively stratified patients into high- low-risk groups showed potential response immunotherapy. Notably, significant differences observed cell abundance between two groups. demonstrated knockdown significantly reduced viability, proliferation, invasion capacity MDA-MB-231 or HCC1806 cells. Conclusion 4-BRG has as an independent biomarker for treatment patients, complementing existing characteristics.

Language: Английский

Citations

10